Description:
Progress in the treatment of myeloma and myeloma bone disease has substantially increased
overall survival, but relapse is inevitable and better treatment is needed. The bone
microenvironment is tremendously complex, so that targeting single interactions between tumor
and bone is unlikely to be effective. Treatments need to block centrally important,
multifunctional pathways. The investigators data point to a central role of the osteocyte to
induce heparanase, a multifunctional mediator of myeloma bone disease. Increased heparanase
due to FGF23 may make systemic inhibitors of heparanase less effective in bone than
elsewhere. FGF23 neutralizing antibodies have been developed for non-cancer conditions of
FGF23 excess, such as chronic kidney disease (Shimada & Fukamoto, 2012), and could be used in
MM alone or in combination with heparanase inhibitors. Complete neutralization of FGF23 has
adverse effects, but neutralization of FGF23 excess may be practical, or in the future,
suppression of excess FGF23 biosynthesis by osteocytes.
The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels
in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this
exploratory study.
Title
- Brief Title: Role of Osteocytes in Myeloma Bone Disease
- Official Title: Role of Osteocytes in Myeloma Bone Disease
Clinical Trial IDs
- ORG STUDY ID:
IUCRO-0498
- NCT ID:
NCT02212262
Conditions
Purpose
Progress in the treatment of myeloma and myeloma bone disease has substantially increased
overall survival, but relapse is inevitable and better treatment is needed. The bone
microenvironment is tremendously complex, so that targeting single interactions between tumor
and bone is unlikely to be effective. Treatments need to block centrally important,
multifunctional pathways. The investigators data point to a central role of the osteocyte to
induce heparanase, a multifunctional mediator of myeloma bone disease. Increased heparanase
due to FGF23 may make systemic inhibitors of heparanase less effective in bone than
elsewhere. FGF23 neutralizing antibodies have been developed for non-cancer conditions of
FGF23 excess, such as chronic kidney disease (Shimada & Fukamoto, 2012), and could be used in
MM alone or in combination with heparanase inhibitors. Complete neutralization of FGF23 has
adverse effects, but neutralization of FGF23 excess may be practical, or in the future,
suppression of excess FGF23 biosynthesis by osteocytes.
The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels
in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this
exploratory study.
Trial Arms
Name | Type | Description | Interventions |
---|
Multiple Myeloma Patients | | Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only. | |
Healthy subjects | | Healthy subjects and multiple myeloma patients will undergo a blood draw | |
Eligibility Criteria
Inclusion Criteria:
1. Age > 18 years but ≤ 95 years at the time of consent
2. Subjects must be English-speaking
3. Must voluntarily sign the most current informed consent and HIPAA documents prior to
study participation.
4. Have no prior history of malignancy in the past 5 years with the exception of basal
cell and squamous cell carcinoma of the skin. Other cancers with low potential for
metastasis, such as in situ cancers can also be enrolled as healthy volunteers.
5. Have no known liver or kidney disorders
Exclusion Criteria:
1. Pregnant females will be excluded from the study.
2. Subjects allergic to xylocaine will be excluded.
3. Subjects with an acute illness (Ex. upper respiratory infection, viral illness) in the
past seven days will be excluded.
4. History of bleeding disorders.
5. Subjects deemed incompetent by treating physician
6. Institutionalized, mentally disabled subjects
7. Subjects who are prisoners
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | Accepts Healthy Volunteers |
Primary Outcome Measures
Measure: | Molecular interactions between multiple myeloma and osteocytes |
Time Frame: | Up to 4 years |
Safety Issue: | |
Description: | To determine FGF23 and heparanase, Dkk1 and plasma klotho levels increase in patients with newly diagnosed and relapsed myeloma compared to healthy controls. |
Secondary Outcome Measures
Measure: | Multiple Myeloma osteocytes and tumor staging |
Time Frame: | Up to 4 years |
Safety Issue: | |
Description: | To correlate the FGF23, heparanase, Dkk1 and plasma klotho to tumor staging |
Measure: | Multiple Myeloma osteocytes and Type I collagen fragments on bone resorption |
Time Frame: | Up to 4 years |
Safety Issue: | |
Description: | To correlate the FGF23, heparanase, Dkk1 and plasma klotho to extent of bone resorption using serum type I collagen fragments ICTP and CTX |
Details
Phase: | |
Primary Purpose: | Observational |
Overall Status: | Recruiting |
Lead Sponsor: | Attaya Suvannasankha |
Last Updated
September 29, 2020